MCL cells express high surface CXCR4 levels, and CXCR4 inhibition by the clinically approved antagonist, Plerixafor (also named AMD3100), reduces MCL cell migration and disrupts microenvironment interaction [16,17,18]. Here, CXCR4 is linked to mantle cell lymphoma.